Status:
COMPLETED
Potassium Supplementation to Reduce Blood Pressure
Lead Sponsor:
Oxford Brookes University
Collaborating Sponsors:
Suntory Beverage & Food Limited
Conditions:
Prehypertension
Eligibility:
All Genders
20-64 years
Phase:
NA
Brief Summary
The aim of this study is to conduct a definitive trial to assess the efficacy of consuming 1L/day of water rich in potassium to reduce blood pressure in mild to moderately hypertensive adults. The obj...
Eligibility Criteria
Inclusion
- Willing and able to provide informed consent
- Between 20 to 64 years old
- English speaking
- Adults who are not receiving antihypertensive pharmacological treatment
- Recent (within 6 months) and latest systolic blood pressure measurement ≥130mmHg and/or diastolic ≥85 mmHg
- Have access to internet and equipment for video calling
- Able to post samples and equipment to OxBCNH
- Physically able to take own body measurements and blood pressure
Exclusion
- Participation in another research study
- Unable to read and understand the instructions provided in English
- Unable to comply with experimental procedures or not follow testing safety guidelines
- People with cardiovascular conditions: heart attack or stroke within the last 3 months, heart failure of grade II New York Heart Association and more severe, or prolonged QT syndrome, angina, arrhythmia or atrial fibrillation.
- Uncontrolled type 2 diabetes (HbA1c\> 9%)
- Type 2 diabetes controlled using exogenous insulin
- Previous or current diagnosis of diabetes complications such as nephropathy, retinopathy and neuropathy.
- People with type 1 diabetes
- Currently on any medication that may lead to hyperkalemia or fluid retention
- Currently being assessed for diagnosis of hypertension (not receiving treatment for high blood pressure)
- Already on clinician/HCP supervised diet or restricted diet
- They are planning on going away from home (holiday or other) during the 4 week intervention period and will not be able to take water during this time.
- Currently prescribed antihypertensive medications, or have been in the last 6 weeks
- Chronic kidney disease stage 1 (G1A2 or G1A3), 2 (G2A2 or G2A3), 3a, 3b, 4 or 5 based on UKKA (we will ask whether participants have been diagnosed with kidney disease by a clinician based on this criteria)
- They are planning to go on a diet or begin taking supplements containing potassium during the intervention
- Pregnant women (including women suspected of being pregnant) and breast-feeding woman.
Key Trial Info
Start Date :
July 30 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05412654
Start Date
July 30 2022
End Date
December 1 2023
Last Update
April 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oxford Brookes University
Oxford, Oxfordshire, United Kingdom, ox30bp